Filter press releases by year
Traditionally, cancer is treated according to tumour types or histology. But with high treatment failure and low survival rates, many oncologists are now realising that it is often critical to understand their patients’ molecular profile.
April 04, 2020
With the escalating severity of the Covid-19 outbreak globally, we wanted to reach out to assure you that we remain fully committed to serving the needs of you and your patients.
Genetic testing can be divided into hereditary cancer genetic testing and tumour genomic profiling. The former can determine whether an individual carries a genetic mutation in hereditary cancer, providing a prediction of the risk of hereditary cancer; the latter helps identify specific genetic mutations that promote cancer growth and assists doctors in selecting drugs specifically for this mutant gene.
Singapore is known the world over for its efficient healthcare system. In fact, the nation nearly tied with Hong Kong in Bloomberg’s global healthcare efficiency index, narrowly missing out on the number one spot by a 1.7 point margin.
April 14, 2019
The global cancer burden is on the rise. According to the World Health Organisation’s International Agency for Research on Cancer (IARC), there were 18.1 million new cancer cases and 9.6 million deaths worldwide in 2018, up from 14.1 million and 8.2 million respectively in 2012ii. Home to 60 percent of the world’s population, Asia contributed to half of all new cases and deaths in 2018.
Precision oncology goes further than just testing for known genomic alterations and treating patients with the medicines available today, says Dr. James Creeden, Global Medical Director of Foundation Medicine.
November 28, 2018
Roche announced last week the launch of FoundationOne CDx, Foundation Medicine’s comprehensive companion diagnostic test for personalised cancer care in Singapore. According to the official media release, FoundationOne CDx supports clinicians in their decision-making by providing a clear, in-depth report that describes the unique genomic profile of a patient’s tumour as well as associated, approved therapies and relevant clinical trials.
November 22, 2018
Multinational healthcare firm Roche has introduced FoundationOne CDx genomic profiling assay in Singapore to guide personalized treatment decisions. FoundationOne CDx, which is Foundation Medicine’s comprehensive companion diagnostic test, will support clinicians in better decision-making.
November 21, 2018
Roche announced today that FoundationOne®CDx, Foundation Medicine’s comprehensive companion diagnostic test for personalized cancer care, has launched in Singapore. FoundationOne CDx supports clinicians in their decision-making by providing a clear, in-depth report that describes the unique genomic profile of a patient’s tumor as well as associated, approved therapies and relevant clinical trials.
FoundationOne CDx analyses the tumour genome to identify clinically relevant genomic alterations in a broad range of cancers and provides insights which can help support treatment decisions.